TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge

被引：0
|
作者：
Sabine Grill
Juliane Ramser
Heide Hellebrand
Nicole Pfarr
Melanie Boxberg
Christine Brambs
Nina Ditsch
Alfons Meindl
Eva Groß
Thomas Meitinger
Marion Kiechle
Anne S. Quante
机构：
[1] University Hospital Klinikum Rechts der Isar,Department of Gynecology and Obstetrics
[2] Technical University Munich (TUM),Institute of Pathology
[3] Technical University Munich (TUM),Department of Gynecology and Obstetrics
[4] University Hospital of Augsburg,Department of Obstetrics and Gynecology
[5] Ludwig-Maximilians-University of Munich,Institute of Human Genetics
[6] University Hospital Klinikum Rechts der Isar,undefined
[7] Technical University Munich (TUM),undefined
来源：
Archives of Gynecology and Obstetrics | 2021年 / 303卷
关键词：
germline mutation; p53; Li-fraumeni-syndrome; Cancer surveillance; Breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1557 / 1567
页数：10
相关论文
共 50 条
  • [21] Germline TP53 mutations in women with very early onset breast cancer (BR).
    Masciari, S
    Harris, L
    Branda, K
    Petkovska, A
    Paez, J
    Haber, D
    Digianni, L
    Sellers, W
    Li, F
    Garber, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 109S - 109S
  • [22] The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations
    Finkova, Alena
    Vazna, Alzbeta
    Hrachovina, Ondrej
    Bendova, Sarka
    Prochazkova, Kamila
    Sedlacek, Zdenek
    [J]. CANCER GENETICS AND CYTOGENETICS, 2009, 193 (01) : 63 - 66
  • [23] Prevalence of germline TP53 mutations in HER2+breast cancer patients
    Rath, Michelle G.
    Masciari, Serena
    Gelman, Rebecca
    Miron, Alexander
    Miron, Penelope
    Foley, Kathleen
    Richardson, Andrea L.
    Krop, Ian E.
    Verselis, Sigitas J.
    Dillon, Deborah A.
    Garber, Judy E.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (01) : 193 - 198
  • [24] Prevalence of germline TP53 mutations in HER2+ breast cancer patients
    Michelle G. Rath
    Serena Masciari
    Rebecca Gelman
    Alexander Miron
    Penelope Miron
    Kathleen Foley
    Andrea L. Richardson
    Ian E. Krop
    Sigitas J. Verselis
    Deborah A. Dillon
    Judy E. Garber
    [J]. Breast Cancer Research and Treatment, 2013, 139 : 193 - 198
  • [25] New surveillance guidelines for Li-Fraumeni and hereditary TP53 related cancer syndrome: implications for germline TP53 testing in breast cancer
    Evans, D. Gareth
    Woodward, Emma R.
    [J]. FAMILIAL CANCER, 2021, 20 (01) : 1 - 7
  • [26] New surveillance guidelines for Li-Fraumeni and hereditary TP53 related cancer syndrome: implications for germline TP53 testing in breast cancer
    D. Gareth Evans
    Emma R. Woodward
    [J]. Familial Cancer, 2021, 20 : 1 - 7
  • [27] The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
    Brachova, Pavla
    Thiel, Kristina W.
    Leslie, Kimberly K.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (09) : 19257 - 19275
  • [28] Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients
    J Alsner
    M Yilmaz
    P Guldberg
    LL Hansen
    J Overgaard
    [J]. Breast Cancer Research, 2 (Suppl 1)
  • [29] Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients
    Alsner, J
    Yilmaz, M
    Guldberg, P
    Hansen, LL
    Overgaard, J
    [J]. CLINICAL CANCER RESEARCH, 2000, 6 (10) : 3923 - 3931
  • [30] Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN
    Blanco, A.
    Grana, B.
    Fachal, L.
    Santamarina, M.
    Cameselle-Teijeiro, J.
    Ruiz-Ponte, C.
    Carracedo, A.
    Vega, A.
    [J]. CLINICAL GENETICS, 2010, 77 (02) : 193 - 196
12345